Second Autologous Hematopoietic Stem Cell Transplant as Salvage Therapy for Relapsed Multiple Myeloma: A Global Treatment Option for Eligible Patients.
作者信息
Gonsalves Wilson I, Kansagra Ankit
机构信息
Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Department of Medicine, Hematology, UT Southwestern, Dallas, Texas, USA.
出版信息
Acta Haematol. 2018;139(1):45-46. doi: 10.1159/000486272. Epub 2018 Jan 18.
Abstract
摘要
相似文献
1
Second Autologous Hematopoietic Stem Cell Transplant as Salvage Therapy for Relapsed Multiple Myeloma: A Global Treatment Option for Eligible Patients.第二次自体造血干细胞移植作为复发多发性骨髓瘤的挽救治疗：适合患者的全球治疗选择。
Acta Haematol. 2018;139(1):45-46. doi: 10.1159/000486272. Epub 2018 Jan 18.
2
When to recommend a second autograft in patients with relapsed myeloma?对于复发性骨髓瘤患者，何时推荐进行第二次自体移植？
Leuk Lymphoma. 2017 Apr;58(4):781-787. doi: 10.1080/10428194.2016.1246729. Epub 2016 Nov 28.
3
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.美国血液与骨髓移植学会、欧洲血液与骨髓移植学会、血液与骨髓移植临床试验网络以及国际骨髓瘤工作组关于复发多发性骨髓瘤患者挽救性造血细胞移植的共识会议
Biol Blood Marrow Transplant. 2015 Dec;21(12):2039-2051. doi: 10.1016/j.bbmt.2015.09.016. Epub 2015 Sep 30.
4
Salvage second transplantation in relapsed multiple myeloma.复发多发性骨髓瘤的挽救性二次移植
Leukemia. 2021 Apr;35(4):1214-1217. doi: 10.1038/s41375-020-1005-8. Epub 2020 Aug 4.
5
Significance of Salvage Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma: A Nationwide Retrospective Study in Japan.挽救性自体干细胞移植对复发多发性骨髓瘤的意义：日本全国性回顾性研究
Acta Haematol. 2018;139(1):35-44. doi: 10.1159/000484652. Epub 2018 Jan 17.
6
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.高剂量化疗联合自体造血干细胞移植作为既往自体造血干细胞移植后复发多发性骨髓瘤患者的巩固治疗（NCRI 骨髓瘤 X 复发[强化试验]）：一项随机、开放标签、3 期试验。
Lancet Oncol. 2014 Jul;15(8):874-85. doi: 10.1016/S1470-2045(14)70245-1. Epub 2014 Jun 16.
7
Reduced-intensity conditioning allogeneic transplantation after salvage treatment with DT-PACE in myeloma patients relapsing early after autologous transplant.自体移植后早期复发的骨髓瘤患者在 DT-PACE 挽救治疗后采用减低强度预处理的异基因移植。
Eur J Haematol. 2017 Oct;99(4):300-305. doi: 10.1111/ejh.12917. Epub 2017 Jul 20.
8
Rationale and design of the multicenter, national, randomized, open labeled phase III trial: allogeneic stem cell transplantation as a potential curative treatment for patients with relapsed or progressed multiple myeloma (AlloRelapseMM Study).多中心、全国性、随机、开放标签的III期试验的原理与设计：异基因干细胞移植作为复发或进展性多发性骨髓瘤患者的一种潜在治愈性治疗方法（异基因复发多发性骨髓瘤研究）
BMC Cancer. 2025 Jan 27;25(1):147. doi: 10.1186/s12885-025-13503-7.
9
Outcomes of Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma Receiving Salvage Cytotoxic Therapy with Supportive Stem Cell Boost.接受挽救性细胞毒性治疗并辅以干细胞强化支持的多次预处理复发/难治性多发性骨髓瘤患者的结局
Curr Stem Cell Res Ther. 2025;20(2):211-217. doi: 10.2174/011574888X287532240325041249.
10
Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation.自体和异体干细胞移植作为自体干细胞移植后复发/进展多发性骨髓瘤的挽救治疗的比较。
Hematol Oncol. 2019 Dec;37(5):586-594. doi: 10.1002/hon.2688. Epub 2019 Nov 23.
引用本文的文献
1
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee.复发/难治性多发性骨髓瘤治疗中的差距和机遇：NCI 多发性骨髓瘤指导委员会的共识建议。
Blood Cancer J. 2022 Jun 29;12(6):98. doi: 10.1038/s41408-022-00695-5.
2
Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma.复发多发性骨髓瘤患者延迟和二次自体干细胞移植后的结果。
Bone Marrow Transplant. 2021 Nov;56(11):2664-2671. doi: 10.1038/s41409-021-01371-1. Epub 2021 Jun 23.
本文引用的文献
1
Significance of Salvage Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma: A Nationwide Retrospective Study in Japan.挽救性自体干细胞移植对复发多发性骨髓瘤的意义：日本全国性回顾性研究
Acta Haematol. 2018;139(1):35-44. doi: 10.1159/000484652. Epub 2018 Jan 17.
2
Autologous stem cell transplant for multiple myeloma patients 70 years or older.70岁及以上多发性骨髓瘤患者的自体干细胞移植
Bone Marrow Transplant. 2016 Nov;51(11):1449-1455. doi: 10.1038/bmt.2016.174. Epub 2016 Jul 4.
3
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.挽救性自体干细胞移植对复发多发性骨髓瘤患者总生存期的影响（英国血液与骨髓移植学会/英国骨髓瘤论坛骨髓瘤X复发[强化治疗]最终结果）：一项随机、开放标签的3期试验
Lancet Haematol. 2016 Jul;3(7):e340-51. doi: 10.1016/S2352-3026(16)30049-7.
4
Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy.自体干细胞治疗后复发的多发性骨髓瘤患者的临床病程及转归
Bone Marrow Transplant. 2016 Aug;51(8):1156-8. doi: 10.1038/bmt.2016.91. Epub 2016 Apr 11.
5
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.多发性骨髓瘤患者的生存率持续提高：老年患者早期死亡率和结局的变化。
Leukemia. 2014 May;28(5):1122-8. doi: 10.1038/leu.2013.313. Epub 2013 Oct 25.
6
Second auto-SCT for treatment of relapsed multiple myeloma.二次自体造血干细胞移植治疗复发性多发性骨髓瘤。
Bone Marrow Transplant. 2013 Apr;48(4):568-73. doi: 10.1038/bmt.2012.183. Epub 2012 Sep 24.
Zotero 插件